-
-
-
-
-
-
-
Goldman Sachs on Ascendis Pharma (ASND): 'in transition to profitability'
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Tops Q2 EPS by 45c
-
-
-
-
-
-
-
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
-
-
-
-
-
-
-
Ascendis Pharma Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Tops Q2 EPS by EUR 37c, Beats on Revenue; Offers FY23 Revenue Guidance
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

